Personalized medicine aims to tailor treatments to individual patients. Until now, this has been done using a small number of parameters to predict the course of a disease.

THURSDAY, Jan. 30, 2025 (HealthDay News) -- The absolute risk for thyroid cancer is low among patients receiving ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

Looking to beat cravings, manage blood sugar levels and shed pounds? Georgetown University–trained biochemist Jessie ...

Clinics in Columbus, Cleveland, Dayton, and Cincinnati have lost their licenses to distribute dangerous drugs after the Ohio ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

A recent study has revealed an increased risk of thyroid cancer diagnoses within the first year of starting GLP-1RA therapy.